Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
November 17, 2022 07:00 ET
|
Invivyd
-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies for COVID-19 and...
Invivyd Reports Third Quarter 2022 Financial Results and Business Highlights
November 10, 2022 16:01 ET
|
Invivyd
Novel monoclonal antibody combination candidate (NVD200) on track to advance into clinical trials in Q1 2023 $419 million in cash, cash equivalents and marketable securities expected to support...
Invivyd to Participate in Fireside Chat at the Jefferies London Healthcare Conference
November 09, 2022 07:00 ET
|
Invivyd
WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases,...
Invivyd to Host Conference Call on November 10 to Discuss Third Quarter 2022 Financial Results and Recent Business Highlights
November 02, 2022 07:00 ET
|
Invivyd
WALTHAM, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases,...
Invivyd Announces the Appointment of Christine Lindenboom to Board of Directors
October 24, 2022 16:01 ET
|
Invivyd
WALTHAM, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Invivyd, Inc. (Nasdaq: IVVD), a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases,...
Invivyd Appoints Fred Driscoll as Interim Chief Financial Officer and Announces Resource Reallocation to Maximize Integrated Discovery Platform
October 13, 2022 16:01 ET
|
Invivyd
WALTHAM, Mass., Oct. 13, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD) a clinical-stage biopharmaceutical company on a mission to protect humanity from serious viral respiratory diseases, today...
Invivyd to Present Multiple Posters Highlighting Clinical Data from Adintrevimab During ID Week 2022
October 12, 2022 16:01 ET
|
Invivyd
WALTHAM, Mass., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Invivyd, (Nasdaq: IVVD), formerly Adagio Therapeutics (Nasdaq: ADGI), a clinical-stage biopharmaceutical company on a mission to protect humanity...
Adagio Therapeutics Announces Corporate Name Change to Invivyd
September 12, 2022 07:00 ET
|
Adagio Therapeutics, Inc.
New name reflects Company focus on leveraging its integrated discovery platform to generate anti-viral antibodies that transcend the limits of naturally occurring immunityThe Invivyd corporate mission...
Adagio Therapeutics to Participate in Upcoming Investor Conferences
September 06, 2022 16:01 ET
|
Adagio Therapeutics, Inc.
WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adagio Therapeutics, Inc. (Nasdaq: ADGI), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of...
Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
August 15, 2022 06:30 ET
|
Adagio Therapeutics, Inc.
$475 Million in Cash and Cash Equivalents to Support Operating Runway into Second Quarter of 2024 Integrated Discovery Platform Identifies Multiple New Candidates for COVID-19 Prevention and...